GB201320061D0 - Materials nad methods for diagnosis and prognosis of liver cancer - Google Patents

Materials nad methods for diagnosis and prognosis of liver cancer

Info

Publication number
GB201320061D0
GB201320061D0 GBGB1320061.3A GB201320061A GB201320061D0 GB 201320061 D0 GB201320061 D0 GB 201320061D0 GB 201320061 A GB201320061 A GB 201320061A GB 201320061 D0 GB201320061 D0 GB 201320061D0
Authority
GB
United Kingdom
Prior art keywords
nad
prognosis
diagnosis
materials
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1320061.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Priority to GBGB1320061.3A priority Critical patent/GB201320061D0/en
Publication of GB201320061D0 publication Critical patent/GB201320061D0/en
Priority to JP2016530873A priority patent/JP2016538545A/ja
Priority to US15/036,773 priority patent/US20160320395A1/en
Priority to CA2928510A priority patent/CA2928510A1/en
Priority to EP14814986.7A priority patent/EP3069142A2/en
Priority to PCT/GB2014/053368 priority patent/WO2015071669A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB1320061.3A 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer Ceased GB201320061D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1320061.3A GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer
JP2016530873A JP2016538545A (ja) 2013-11-13 2014-11-13 肝臓癌の診断及び予後判定のための材料及び方法
US15/036,773 US20160320395A1 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer
CA2928510A CA2928510A1 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer
EP14814986.7A EP3069142A2 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer
PCT/GB2014/053368 WO2015071669A2 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1320061.3A GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer

Publications (1)

Publication Number Publication Date
GB201320061D0 true GB201320061D0 (en) 2013-12-25

Family

ID=49818578

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1320061.3A Ceased GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer

Country Status (6)

Country Link
US (1) US20160320395A1 (https=)
EP (1) EP3069142A2 (https=)
JP (1) JP2016538545A (https=)
CA (1) CA2928510A1 (https=)
GB (1) GB201320061D0 (https=)
WO (1) WO2015071669A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288659B (zh) * 2015-06-01 2019-07-26 北京泱深生物信息技术有限公司 Tenm1基因及其表达产物在诊治乳头状腺癌的应用
KR101750411B1 (ko) 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
EP3403100B1 (fr) * 2016-01-15 2020-03-11 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Procédé de diagnostic in vitro d'atteintes hépatiques
FR3048780B1 (fr) * 2016-03-11 2020-11-06 Commissariat Energie Atomique Procede de diagnostic in vitro d'atteintes hepatiques
GB201616912D0 (en) * 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
CN115266962B (zh) * 2017-03-31 2024-05-31 北京谷海天目生物医学科技有限公司 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
WO2018189215A1 (en) * 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
CN109596829A (zh) * 2017-12-07 2019-04-09 南京医科大学 一种肝癌标志蛋白及其检测方法
WO2019115679A1 (en) * 2017-12-13 2019-06-20 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol A signature to assess prognosis and therapeutic regimen in liver cancer
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
US20220244263A1 (en) * 2019-05-28 2022-08-04 The Regents Of The University Of California Methods for treating small cell neuroendocrine and related cancers
BR112022015303A2 (pt) * 2020-02-10 2022-09-27 Somalogic Operating Co Inc Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos
WO2021175863A1 (en) * 2020-03-02 2021-09-10 Université De Strasbourg Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
JP7471898B2 (ja) * 2020-04-17 2024-04-22 合同会社Ｈ．Ｕ．グループ中央研究所 胆管がんのバイオマーカー
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
CN112961916B (zh) * 2020-11-10 2024-03-12 上海市肿瘤研究所 Akr1c3作为肝癌预后的生物学标志物及其应用
CN112908470B (zh) * 2021-02-08 2023-10-03 深圳市人民医院 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用
CN113462777A (zh) * 2021-06-28 2021-10-01 武汉大学 P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用
CN114814001B (zh) * 2022-03-31 2023-02-21 武汉大学 用于制备肝癌检测试剂的新型代谢标志物及其应用
CN115754290A (zh) * 2022-09-26 2023-03-07 浙江大学 一种用于检测早期肝癌的试剂盒
CN115807089B (zh) * 2022-11-14 2024-09-13 石河子大学 肝细胞肝癌预后生物标志物及应用
CN116338189B (zh) * 2023-01-16 2025-08-22 浙江大学医学院附属第一医院 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用
CN116386715A (zh) * 2023-03-09 2023-07-04 福建医科大学孟超肝胆医院 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用
CN117607438A (zh) * 2023-11-23 2024-02-27 浙江大学 一种肝细胞癌鉴别诊断和分化程度检测方法
CN119314683B (zh) * 2024-12-17 2025-02-25 吉林大学第一医院 一种用于肝移植术后预测系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE508361T1 (de) 2001-08-14 2011-05-15 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
EP1831697A4 (en) * 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
JPWO2009113495A1 (ja) * 2008-03-12 2011-07-21 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物

Also Published As

Publication number Publication date
CA2928510A1 (en) 2015-05-21
EP3069142A2 (en) 2016-09-21
US20160320395A1 (en) 2016-11-03
WO2015071669A3 (en) 2015-09-17
JP2016538545A (ja) 2016-12-08
WO2015071669A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
GB201320061D0 (en) Materials nad methods for diagnosis and prognosis of liver cancer
EP3057620A4 (en) Methods of using spect/ct analysis for staging cancer
SG10201703022SA (en) Method of prognosis and stratification of ovarian cancer
GB201317622D0 (en) Cancer biomarkers and uses thereof
ZA201400089B (en) Methods and nucleic acids for determining the prognosis of a cancer subject
SG11201507427QA (en) Compositions and methods for diagnosis and treatment of hepatic cancers
EP2971177A4 (en) COMPOSITIONS AND METHODS FOR DETECTING AND DETERMINING A PROSTATE CANCER PROGNOSTIC
EP2867376A4 (en) TARGETED METHODS KNOWN AS RNA-SEQ AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCER
SG11201510210XA (en) Methods for detecting prostate cancer
EP2988659A4 (en) Improved methods of cancer detection
IL236197A0 (en) In vitro method for the diagnosis and surveillance of cancer
EP3052661A4 (en) Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens
EP2986326A4 (en) Methods for detecting cancer metastasis
SG11201606106SA (en) Specific biomarker set for non-invasive diagnosis of liver cancer
SG11201602170XA (en) Anti-epcam antibodies and methods of use
EP2968192A4 (en) Methods and materials for detection of biologicals
EP2965086A4 (en) Methods of detecting prostate cancer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
ZA201604370B (en) Prostate cancer gene profiles and methods of using the same
EP2977760A4 (en) Biomarker for diagnosing liver cancer
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
GB2511520B (en) Methods for construction and completion of underwater tunnels
EP3058101A4 (en) Serum mirnas for the prognosis of prostate cancer
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
PL2979096T3 (pl) Integryna alfa-v-beta-6 do diagnozowania/prognozowania raka okrężnicy i odbytnicy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)